Adicet Bio, Inc. (ACET)
Largest Insider Buys in Sector
ACET Stock Price History Chart
ACET Stock Performance
About Adicet Bio, Inc.
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company …
Insider Activity of Adicet Bio, Inc.
Over the last 12 months, insiders at Adicet Bio, Inc. have bought $15M and sold $8,437 worth of Adicet Bio, Inc. stock.
On average, over the past 5 years, insiders at Adicet Bio, Inc. have bought $10.89M and sold $2.2M worth of stock each year.
Highest buying activity among insiders over the last 12 months: ORBIMED ADVISORS LLC () — $315M. GORDON CARL L () — $97.5M.
The last purchase of 3,125,000 shares for transaction amount of $7.5M was made by ORBIMED ADVISORS LLC () on 2024‑01‑25.
List of Insider Buy and Sell Transactions, Adicet Bio, Inc.
| 2024-06-05 | Sale | director | 5,900 0.0071% | $1.43 | $8,437 | -4.17% | ||
| 2024-01-25 | 3.13M 7.0488% | $2.40 | $7.5M | -39.68% | ||||
| 2024-01-25 | 3.13M 7.0488% | $2.40 | $7.5M | -39.68% | ||||
| 2023-10-02 | President & CEO | 5,500 0.013% | $1.33 | $7,340 | +15.27% | |||
| 2023-09-29 | Sale | President & CEO | 5,500 0.0127% | $1.36 | $7,481 | +10.22% | ||
| 2023-09-28 | Sale | President & CEO | 5,500 0.0128% | $1.42 | $7,810 | +6.34% | ||
| 2023-09-28 | President & CEO | 5,500 0.0128% | $1.42 | $7,810 | +6.34% | |||
| 2023-06-30 | director | 5,000 0.0115% | $2.40 | $12,000 | -27.98% | |||
| 2023-06-27 | 875,000 1.9987% | $2.09 | $1.83M | -16.90% | ||||
| 2023-06-27 | 875,000 1.9987% | $2.09 | $1.83M | -16.90% | ||||
| 2023-02-15 | Sale | Chief Technology Officer | 4,533 0.0101% | $7.57 | $34,327 | -67.81% | ||
| 2023-02-10 | Sale | Chief Technology Officer | 10,467 0.0247% | $7.98 | $83,476 | -67.94% | ||
| 2022-11-10 | Sale | President & CEO | 39,955 0.095% | $20.30 | $811,242 | -72.55% | ||
| 2022-11-10 | Sale | Chief Scientific Officer | 6,967 0.0171% | $21.00 | $146,307 | -72.55% | ||
| 2022-11-07 | Sale | President & CEO | 30,000 0.0726% | $19.05 | $571,488 | -69.89% | ||
| 2022-11-03 | Sale | President & CEO | 24,813 0.06% | $18.04 | $447,718 | -68.13% | ||
| 2022-11-02 | Sale | President & CEO | 500 0.0013% | $18.00 | $9,000 | -66.31% | ||
| 2022-10-19 | Sale | Chief Scientific Officer | 8,067 0.0198% | $16.27 | $131,250 | -62.10% | ||
| 2022-10-12 | Sale | Chief Scientific Officer | 1,646 0.0039% | $15.40 | $25,348 | -61.34% | ||
| 2022-09-14 | Sale | President & CEO | 952 0.0023% | $18.00 | $17,136 | -57.90% |
Insider Historical Profitability
| ORBIMED ADVISORS LLC | 7526359 9.1338% | $0.91 | 3 | 0 | <0.0001% | |
| GORDON CARL L | 7526359 9.1338% | $0.91 | 2 | 0 | <0.0001% | |
| SILVERSTEIN JONATHAN | 4830387 5.862% | $0.91 | 1 | 0 | ||
| PureTech Health LLC | 10 percent owner | 2119696 2.5724% | $0.91 | 1 | 6 | |
| Sinclair Andrew | director | 2115385 2.5672% | $0.91 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| OrbiMed | $26.9M | 13.93 | 11.45M | +37.55% | +$7.34M | 0.21 | |
| RA Capital Management, L.P. | $17.72M | 9.18 | 7.54M | New | +$17.72M | 0.02 | |
| Tang Capital Management, LLC | $15.06M | 7.8 | 6.41M | +631.14% | +$13M | 0.06 | |
| Balyasny Asset Management Llc | $14.53M | 7.52 | 6.18M | New | +$14.53M | 0.04 | |
| RTW Investments, LP | $9.72M | 5.03 | 4.13M | 0% | +$0 | 0.15 |